Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Public ClinicalTrials.gov record NCT00715208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone (VELCADE-R-CP) based on investigator preference. Following completion of the treatment period, patients will receive maintenance therapy with rituximab up to a maximum of 2 years.
Study identification
- NCT ID
- NCT00715208
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- rituximab Drug
- cyclophosphamide Drug
- doxorubicin Drug
- VELCADE Drug
- prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2008 (Type not available)
- Primary completion
- Feb 2011 (Actual)
- Completion
- Mar 2011 (Actual)
- Last update posted
- Apr 29, 2013
2008 – 2011
United States locations
- U.S. sites
- 42
- U.S. states
- 29
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwest Alabama Center, PC | Muscle Shoals | Alabama | 35661 | — |
| Providence Saint Joseph Medical Center | Burbank | California | 91505 | — |
| Pacific Coast Hematology Oncology Medical Group | Fountain Valley | California | 92708 | — |
| Loma Linda U Cancer Center | Loma Linda | California | 92354 | — |
| Desert Hematology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| Cancer Center of Central Connecticut | Southington | Connecticut | 06498 | — |
| Ocala Cancer Institute | Ocala | Florida | 34471 | — |
| Northwest Georgia Oncology Centers, PC | Marietta | Georgia | 30060 | — |
| Southern Illinois Hematology Oncology | Centralia | Illinois | 62801 | — |
| Alexian Brothers Hospital Network | Elk Grove Village | Illinois | 60007 | — |
| Clintell, Inc. | Skokie | Illinois | 60077 | — |
| Cancer Care Center, Inc. | New Albany | Indiana | 47150 | — |
| Siouxland Hematology Oncology Associates | Sioux City | Iowa | 51101 | — |
| Hutchinson Clinic | Hutchinson | Kansas | 67502 | — |
| Purchase Cancer Group | Paducah | Kentucky | 42001 | — |
| Medical Oncology, LLC | Baton Rouge | Louisiana | 70809 | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Kalamazoo Hematology and Oncology | Kalamazoo | Michigan | 49048 | — |
| Jackson Oncology Associates, PLLC | Jackson | Mississippi | 39202 | — |
| St. Louis Cancer Care, LLP | Chesterfield | Missouri | 63017 | — |
| Nebraska Hematology-Oncology, PC | Lincoln | Nebraska | 68506 | — |
| Great Plains Regional Medical Center | North Platte | Nebraska | 69101 | — |
| Southern Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| NYU Clinical Cancer Center | New York | New York | 10016 | — |
| Interlakes Foundation | Rochester | New York | 14623 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Oklahoma Oncology and Hematology, PC | Oklahoma City | Oklahoma | 73112 | — |
| Oklahoma Oncology and Hematology, PC | Tulsa | Oklahoma | 74136 | — |
| Temple University | Philadelphia | Pennsylvania | 19140 | — |
| Allegheny-Singer Research Institute | Pittsburgh | Pennsylvania | 15212 | — |
| Western Pennsylvania Cancer Institute | Pittsburgh | Pennsylvania | 15224 | — |
| Landmark Medical Center | Woonsocket | Rhode Island | 02895 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| HOPE Oncology | Richardson | Texas | 75080 | — |
| Northern Utah Associates | Ogden | Utah | 84403 | — |
| Marshall University | Huntington | West Virginia | 25701 | — |
| West Virginia University Health Science Center | Morgantown | West Virginia | 26505 | — |
| Marshfield Clinic | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00715208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2013 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00715208 live on ClinicalTrials.gov.